Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425292 · ClinicalTrials.gov registry record · Phase 1
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
A Phase 1 study, sponsored by Saint John's Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03425292: Completed Phase 1 study, sponsored by Saint John's Cancer Institute.
NCT03425292 is a Phase 1 study that has completed, run by Saint John's Cancer Institute. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03425292, a Phase 1 study, has completed, sponsored by Saint John's Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of the research study drugs nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery and before standard therapy with radiation and temozolomide in patients with newly diagnosed high grade glioma. Additional aims of the study are to: * Find out side effects (good and bad) of study drug combinations. * Evaluate any preliminary evidence of anticancer activity of study drug combinations . * Evaluate tumor characteristics by collecting brain tumor tissue samples. * Measure the amount of nivolumab and ipilimumab in biospecimens. * Look at biomarkers in biospecimens.
Primary Outcome
treatment-related adverse events that impact administration of treatment
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Temozolomide
- RADIATION conformal brain radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 1 |
What the finished NCT03425292 record still lists
NCT03425292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03425292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03425292 about?
NCT03425292 is a clinical study titled "A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer". The purpose of this study is to test the safety and tolerability of the research study drugs nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery and before standard therapy with radiation and temozolomide in patients with newly diagnosed high grade glioma. Ad...
What is the current status of trial NCT03425292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-03-01. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT03425292?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Temozolomide (DRUG), conformal brain radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03425292?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03425292's enrollment target sits among peer trials
49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI